Youssef Tazi

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11

Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group

Pierre-Étienne Heudel, Michel Fabbro, C. Roemer-Bécuwe et al. · British Journal of Cancer · 2017 · 64 citations · Full text

Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial

Antonio González-Martı́n, Christophe Desauw, Florian Heitz et al. · European Journal of Cancer · 2022 · 63 citations · Full text

Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group

C. Hober, Lisa Fredeau, Anne Pham‐Ledard et al. · Cancers · 2021 · 55 citations · Full text

Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial

Giulia Baciarello, R. Delva, Gwénaëlle Gravis et al. · European Urology · 2021 · 39 citations

Urology, Medicine, Cancer Management +7